Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has entered into a definitive agreement to acquire the global rights to TYRVAYA nasal spray from Viatris Inc. for $30 million in cash at closing and up to $70 million in potential milestone payments. The acquisition complements Harrow's flagship VEVYE franchise by adding a nasal spray treatment for dry eye disease, creating a broader portfolio of differentiated options for patients.
Key figures
- Deal Value Usd
- 100000000
- Upfront payment usd
- 30000000
- Contingent milestone payments usd
- 70000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.